Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden.

Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden.:

Related Articles

Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden.

Ann Oncol. 2019 May;30(5):744-756

Authors: Hashim D, Genden E, Posner M, Hashibe M, Boffetta P

Abstract

Survival from head and neck cancers (HNCs) of the lip, oral cavity, pharynx, and larynx has increased by 10% over the past few decades. Little over half of patients who develop HNCs will survive beyond 5 years. Survival is lower for individuals in many countries where traditional risk factors such as tobacco smoking, alcohol drinking, and betel quid chewing are highly prevalent but tertiary health care center access is limited or unavailable. Early diagnosis of HNC is the most important prognostic factor for each tumor site. Molecular-based research on HNC tumors holds promise for early stage detection, screening, vaccination, disease follow-up, and progression. Future investments for HNC control must consider both effectiveness and sustainability for both high- and low-resource countries alike, with priority toward risk factor prevention and earlier diagnosis.

PMID: 31987341 [PubMed - in process]